Cargando…
Discovery of small molecules targeting the tandem tudor domain of the epigenetic factor UHRF1 using fragment-based ligand discovery
Despite the established roles of the epigenetic factor UHRF1 in oncogenesis, no UHRF1-targeting therapeutics have been reported to date. In this study, we use fragment-based ligand discovery to identify novel scaffolds for targeting the isolated UHRF1 tandem Tudor domain (TTD), which recognizes the...
Autores principales: | Chang, Lyra, Campbell, James, Raji, Idris O., Guduru, Shiva K. R., Kandel, Prasanna, Nguyen, Michelle, Liu, Steven, Tran, Kevin, Venugopal, Navneet K., Taylor, Bethany C., Holt, Matthew V., Young, Nicolas L., Samuel, Errol L. G., Jain, Prashi, Santini, Conrad, Sankaran, Banumathi, MacKenzie, Kevin R., Young, Damian W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806715/ https://www.ncbi.nlm.nih.gov/pubmed/33441849 http://dx.doi.org/10.1038/s41598-020-80588-4 |
Ejemplares similares
-
The histone and non-histone methyllysine reader activities of the UHRF1 tandem Tudor domain are dispensable for the propagation of aberrant DNA methylation patterning in cancer cells
por: Vaughan, Robert M., et al.
Publicado: (2020) -
Tudor Arghezi
por: Micu, Dumitru -
Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes
por: Li, Feng, et al.
Publicado: (2020) -
Marie Tudor : La Esmeralda : Angelo /
por: Hugo, Victor, 1802-1885
Publicado: (1935) -
Discovery and characterization of bromodomain 2–specific inhibitors of BRDT
por: Yu, Zhifeng, et al.
Publicado: (2021)